Vote Scores
Filings read through

Summit Therapeutics Inc.: how funds voted at the meeting of 12 Jun 2025

Ticker
SMMT
Meeting
Season
year to 30 June 2025
Filers reporting
320
Ballot items
3

320 filers on Form N-PX reported votes at the Summit Therapeutics Inc. meeting of 12 Jun 2025. The records fall into 3 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

This meeting is in the year to 30 June 2025. The latest season on file is the year to 30 June 2026. The page of Summit Therapeutics Inc. has the latest meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2025. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    9 nominees. 72.2% of the reported votes are for. 89 filers withheld from or voted against at least one nominee.

    1,946 vote records from 112 filers. 33 of the 110 filers that marked the item voted against management. 2 filers gave no management mark.

    • Positions of 33 fund families
    • For 21
    • Against 12
    • Against management 12
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    473 vote records from 318 filers. 155 of the 299 filers that marked the item voted against management. 19 filers gave no management mark.

    • Positions of 40 fund families
    • For 15
    • Against 24
    • Split or no vote 1
    • Against management 23
  3. Item 3: Audit-related items (auditor ratification)

    216 vote records from 112 filers. 2 of the 110 filers that marked the item voted against management. 2 filers gave no management mark.

    • Positions of 33 fund families
    • For 33

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Summit Therapeutics Inc., meeting of 12 Jun 2025Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Auditor
AllianceBernsteinAgainst, against managementNo report
American CenturyAgainst, against managementFor
Artisan PartnersSplitNo report
BlackRock and iSharesForFor
BNY MellonAgainst, against managementFor
Brighthouse FundsAgainst, against managementFor
Charles SchwabForFor
Columbia ThreadneedleAgainst, against managementFor
DimensionalAgainst, against managementNo report
DWSAgainst, against managementFor
EquitableAgainst, against managementFor
FidelityAgainst, against managementFor
First TrustAgainst, against managementFor
Franklin TempletonAgainst, against managementFor
Global XForFor
Goldman SachsAgainst, against managementFor
Guggenheim and RydexAgainst, against managementFor
InvescoAgainst, against managementNo report
J.P. MorganAgainst, against managementFor
Jackson National fundsAgainst, against managementFor
John Hancock and ManulifeAgainst, against managementFor
Lincoln FinancialAgainstFor
Lord AbbettForNo report
Morgan Stanley, Eaton Vance and CalvertAgainst, against managementFor
NationwideForFor
Neuberger BermanForNo report
Northern Trust and FlexSharesForFor
Nuveen and TIAAForFor
Pacific Life fundsForFor
PGIM and PrudentialForNo report
PrincipalAgainst, against managementFor
ProShares and ProFundsAgainst, against managementFor
Russell InvestmentsForFor
SEIForFor
State Street and SPDRForFor
T. Rowe PriceAgainst, against managementFor
VanguardForFor
Victory CapitalAgainst, against managementFor
VirtusForFor
VoyaAgainst, against managementFor

Questions

How many filers reported votes at the Summit Therapeutics Inc. meeting?
320 Form N-PX filers reported votes at the meeting of 12 Jun 2025. On say-on-pay, 155 of 299 filers that marked the item voted against management (51.8%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Summit Therapeutics Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Summit Therapeutics Inc. with a meeting date within three days of 12 Jun 2025. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .